CoChat

Transcriptional regulation of the MET receptor tyrosine kinase gene by MeCP2 and sex-specific expression in autism and Rett syndrome

Open access
Plummer, J T, Evgrafov, O V, Bergman, M Y, Friez, M, Haiman, C A, Levitt, P, Aldinger, K A · 2013 · Translational Psychiatry
Cited by 37

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Single nucleotide variants (SNV) in the gene encoding the MET receptor tyrosine kinase have been associated with an increased risk for autism spectrum disorders (ASD). The MET promoter SNV rs1858830 C 'low activity' allele is enriched in ASD, associated with reduced protein expression, and impacts functional and structural circuit connectivity in humans. To gain insight into the transcriptional regulation of MET on ASD-risk etiology, we examined an interaction between the methyl CpG-binding protein 2 (MeCP2) and the MET 5' promoter region. Mutations in MeCP2 cause Rett syndrome (RTT), a predominantly female neurodevelopmental disorder sharing some ASD clinical symptoms. MeCP2 binds to a region of the MET promoter containing the ASD-risk SNV, and displays rs1858830 genotype-specific binding in human neural progenitor cells derived from the olfactory neuroepithelium. MeCP2 binding enhances MET expression in the presence of the rs1858830 C allele, but MET transcription is attenuated by RTT-specific mutations in MeCP2. In the postmortem temporal cortex, a region normally enriched in MET, gene expression is reduced dramatically in females with RTT, although not due to enrichment of the rs1858830 C 'low activity' allele. We newly identified a sex-based reduction in MET expression, with male ASD cases, but not female ASD cases compared with sex-matched controls. The experimental data reveal a prominent allele-specific regulation of MET transcription by MeCP2. The mechanisms underlying the pronounced reduction of MET in ASD and RTT temporal cortex are distinct and likely related to factors unique to each disorder, including a noted sex bias.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/tp.2013.91

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 42

  1. State MW, Levitt P . The conundrums of understanding genetic risks for autism spectrum disorders. Nat Neurosci 2011; 14: 1499–1506. · DOI · Paper page
  2. Scherer SW, Dawson G . Risk factors for autism: translating genomic discoveries into diagnostics. Hum Genet 2011; 130: 123–148. · DOI
  3. Sousa I, Clark TG, Toma C, Kobayashi K, Choma M, Holt R et al. MET and autism susceptibility: family and case-control studies. Eur J Hum Genet 2009; 17: 749–758. · DOI · Paper page
  4. Judson MC, Eagleson KL, Wang L, Levitt P . Evidence of cell-nonautonomous changes in dendrite and dendritic spine morphology in the met-signaling-deficient mouse forebrain. J Comp Neurol 2010; 518: 4463–4478. · DOI · Paper page
  5. Judson MC, Eagleson KL, Levitt P . A new synaptic player leading to autism risk: MET receptor tyrosine kinase. J Neurodev Disord 2011; 3: 282–292. · DOI · Paper page
  6. Trusolino L, Bertotti A, Comoglio PM . MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834–848. · DOI · Paper page
  7. Liang H, O’Reilly S, Liu Y, Abounader R, Laterra J, Maher VM et al. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity. Int J Oncol 2004; 24: 1057–1067.
  8. Mascarenhas JB, Young KP, Littlejohn EL, Yoo BK, Salgia R, Lang D . PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem 2009; 284: 27524–27532. · doi:10.1074/jbc.m109.047209
  9. Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet 2010; 6: e1000917. · DOI · Paper page
  10. Lai CS, Gerrelli D, Monaco AP, Fisher SE, Copp AJ . FOXP2 expression during brain development coincides with adult sites of pathology in a severe speech and language disorder. Brain 2003; 126: 2455–2462. · DOI · Paper page
  11. Mukamel Z, Konopka G, Wexler E, Osborn GE, Dong H, Bergman MY et al. Regulation of MET by FOXP2, genes implicated in higher cognitive dysfunction and autism risk. J Neurosci 2011; 31: 11437–11442. · DOI · Paper page
  12. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Franke U, Zoghbi HY . Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999; 23: 185–188. · DOI · Paper page
  13. Ramocki MB, Tavyev YJ, Peters SU . The MECP2 duplication syndrome. Am J Med Genet A 2010; 152A: 1079–1088. · DOI · Paper page
  14. Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A, Cuccaro ML et al. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr Neurol 2003; 28: 205–211. · DOI · Paper page
  15. Evgrafov OV, Wrobel BB, Kang X, Simpson G, Malaspina D, Knowles JA . Olfactory neuroepithelium-derived neural progenitor cells as a model system for investigating the molecular mechanisms of neuropsychiatric disorders. Psychiatr Genet 2011; 21: 217–228. · DOI
  16. Shimohigashi Y, Hatano R, Fujita T, Nakashima R, Nose T, Sujaku T et al. Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide. J Biol Chem 1996; 271: 23642–23645. · doi:10.1074/jbc.271.39.23642
  17. Aldinger KA, Plummer JT, Levitt P . Comparative DNA methylation among females with neurodevelopmental disorders and seizures identifies TAC1 as a MeCP2 target gene. J Neurodev Disord 2013; 5: 15. · DOI
  18. Kerin T, Ramanathan A, Rivas K, Grepo N, Coetzee GA, Campbell DB . A noncoding RNA antisense to moesin at 5p14.1 in autism. Sci Transl Med 2012; 4: 9–14. · DOI · Paper page
  19. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000; 151: 346–357. · DOI · Paper page
  20. Moretti P, Zoghbi HY . MeCP2 dysfunction in Rett syndrome and related disorders. Curr Opin Genet Dev 2006; 16: 276–281. · DOI · Paper page
  21. Guy J, Cheval H, Selfridge J, Bird A . The role of MeCP2 in the brain. Ann Rev Cell Dev Biol 2011; 27: 631–652. · DOI · Paper page
  22. Judson MC, Amaral DG, Levitt P . Conserved subcortical and divergent cortical expression of proteins encoded by orthologs of the autism risk gene MET. Cereb Cortex 2011; 21: 1613–1626. · DOI · Paper page
  23. Abecasis GR, Auton A, Books LD, DePristo MA, Durbin RM, Handsaker RE et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56–65. · DOI · Paper page
  24. Campbell DB, Warren D, Sutcliffe JS, Lee EB, Levitt P . Association of MET with social and communication phenotypes in individuals with autism spectrum disorder. Am J Med Genet B Neuropsychiatr Genet 2012; 153B: 438–446. · DOI · Paper page
  25. Bird A . The methyl-CpG-binding protein MeCP2 and neurological disease. Biochem Soc Trans 2008; 36: 575–583. · DOI · Paper page
  26. Nan X, Campoy FJ, Bird A . MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997; 88: 471–481. · DOI · Paper page
  27. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386–389. · DOI · Paper page
  28. Meehan RR, Lewis JD, Bird AP . Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res 1992; 20: 5085–5092. · DOI · Paper page
  29. McGinty JF . The many faces of MeCP2. Neuropsychopharmacology 2012; 37: 313–314. · DOI
  30. Tudor M, Akbarian S, Chen RZ, Jaenisch R . Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci U S A 2002; 99: 15536–15541. · DOI · Paper page
  31. Nectoux J, Fichou Y, Rosas-Vargas H, Cagnard N, Bahi-Buisson N, Nusbaum P et al. Cell cloning-based transcriptome analysis in Rett patients: relevance to the pathogenesis of Rett syndrome of new human MeCP2 target genes. J Cell Mol Med 2010; 14: 1962–1974. · DOI
  32. Ballestar E, Yusufzai TM, Wolffe AP . Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. Biochemistry 2000; 39: 7100–7106. · DOI · Paper page
  33. Colantuoni C, Jeon OH, Hyder K, Chenchik A, Khimani AH, Narayanan V et al. Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. Neurobiol Dis 2001; 8: 847–865. · DOI · Paper page
  34. Delgado IJ, Kim DS, Thatcher KN, LaSalle JM, Van den Veyver IB . Expression profiling of clonal lymphocyte cell cultures from Rett syndrome patients. BMC Med Genet 2006; 7: 61. · DOI · Paper page
  35. Deng V, Matagne V, Bamine F, Frerking M, Ohliger P, Budden S et al. FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. Hum Mol Genet 2007; 16: 640–650. · DOI · Paper page
  36. Gibson JH, Slobedman B, KN H, Williamson SL, Minchenko D, El-Osta A et al. Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain. BMC Neurosci 2010; 11: 53. · DOI · Paper page
  37. Abuhatzira L, Makedonski K, Kaufman Y, Razin A, Shemer R . MeCP2 deficiency in the brain decreases BDNF levels by REST/CoREST-mediated repression and increases TRKB production. Epigenetics 2007; 2: 214–222. · DOI · Paper page
  38. Swanberg SE, Nagarajan RP, Peddada S, Yasui DH, LaSalle JM . Reciprocal co-regulation of EGR2 and MECP2 is disrupted in Rett syndrome and autism. Hum Mol Genet 2009; 18: 525–534. · DOI · Paper page
  39. Zocchi L, Sassone-Corsi P . SIRT1-mediated deacetylation of MeCP2 contributes to BDNF expression. Epigenetics 2012; 7: 695–700. · DOI · Paper page
  40. Kishi N, Macklis JD . MeCP2 functions largely cell-autonomously, but also non-cell-autonomously, in neuronal maturation and dendritic arborization of cortical pyramidal neurons. Exp Neurol 2010; 222: 51–58. · DOI · Paper page
  41. Eagleson KL, Campbell DB, Thompson BL, Bergman MY, Levitt P . The autism risk genes MET and PLAUR differentially impact cortical development. Autism Res 2011; 4: 68–83. · DOI · Paper page
  42. Thanseem I, Nakamura K, Miyachi T, Toyota T, Yamada S, Tsujii M et al. Further evidence for the role of MET in autism susceptibility. Neurosci Res 2010; 68: 137–141. · DOI

Cited by

See all 37

Metadata

Authors
Plummer, J. T., Evgrafov, O. V., Bergman, M. Y., Friez, M., Haiman, C. A., Levitt, P., & Aldinger, K. A.
Venue
Translational Psychiatry
Published
2013-10-22
Volume
3
Issue
10
Pages
e316-e316
ISSN
2158-3188 (ISSN-L)
OpenAlex
W2046925087
Cited by
37
References
32
FWCI
2.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.